Navigation Links
AcelRx Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Health Care Conference
Date:11/23/2011

REDWOOD CITY Calif., Nov. 23, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at the 23rd Annual Piper Jaffray Health Care Conference in New York City at the New York Palace Hotel.  The presentation is scheduled for Tuesday, November 29 at 9:30 a.m. ET.

The presentation will be webcast live and can be accessed through: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ACRX&item_id=4228786.  For those who are not available to listen to the live broadcast, the presentation will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in preparation for Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. A fourth product candidate, ARX-04, is a sufentanil product for the treatment of moderate-to-severe acute pain that is expected to enter Phase 2 clinical development in the fourth quarter of 2011 under a grant from the US Army Medical Research and Material Command.


'/>"/>
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... 16, 2017  According to Kalorama Information, the ... valued at $4.9 billion for 2016.  The growing ... an aging population with significant diagnostic needs, along ... propelling the market for the modality.  The healthcare ... , focuses on the worldwide market, providing market ...
(Date:1/16/2017)... , January 16, 2017 ... Derivatives Market by Product Type (Methyl, Ethyl, Hydroxyethyl, ... Foods & Beverages, Surface Coatings & Paints), ... by MarketsandMarkets, the market was valued at ... projected to reach USD 6.41 Billion by ...
(Date:1/16/2017)... CRUZ, Calif. , Jan. 16, 2017  Dovetail ... Dovetail™ Hi-C sequencing and assembly service, which yields chromosome-scale ... be presented in a Dovetail-hosted workshop on Jan. 17 ... in San Diego . ... services with the launch of our Dovetail Hi-C offering," ...
Breaking Medicine Technology:
(Date:1/15/2017)... ... January 15, 2017 , ... In this role, Courtney ... United States for the asthma & allergy friendly mark. This certification program was created ... and identify consumer products to be more suitable for the 60+ million people living ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed ... and ease," said Christina Austin - CEO of Pixel Film Studios. , On ... edit the style and animation of their slideshows. Place each slide on top of ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... NJ is pleased to announce that it will be assisting HackensackUMC Mountainside with ... and Glen Ridge townships, servicing all surrounding towns. The firm will be working ...
(Date:1/14/2017)... ... 2017 , ... "TransFreeze Volume 3 is a self animating masking transition which allows users to ... X," said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 ... one clip to the next. , To use “Cut-Out First” presets, choose a ...
(Date:1/13/2017)... ... 13, 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth ... companion scanner and data collector at the National Retail Federation’s Big Show (NRF17) held ... answer to the market’s need for more compact and rugged devices for collecting barcode ...
Breaking Medicine News(10 mins):